Syneos Health (NASDAQ:SYNH) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.59. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.93 billion.Syneos Health also updated its FY 2020
After-Hours guidance to 3.58-3.78 EPS.
NASDAQ SYNH traded up $0.45 during trading hours on Thursday, hitting $62.95. The company’s stock had a trading volume of 12,125 shares, compared to its average volume of 407,380. Syneos Health has a 12 month low of $36.72 and a 12 month high of $64.72. The company’s 50 day simple moving average is $57.68 and its two-hundred day simple moving average is $53.16. The company has a market cap of $6.61 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 1.79 and a beta of 1.52. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.03 and a quick ratio of 1.03.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.82 by $0.05. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.18 billion. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. Syneos Health’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. As a group, research analysts predict that Syneos Health will post 2.81 earnings per share for the current fiscal year.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: What is a dividend reinvestment plan?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.